Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Healthy Tissue Uptake of 68Ga-Prostate Specific Membrane Antigen (PSMA), 18F-DCFPyL, 18F-Fluoromethylcholine (FCH) and 18F-Dihydrotestosterone (FDHT)

Bernard H.E. Jansen, Gerbrand M. Kramer, Matthijs C.F. Cysouw, Maqsood M. Yaqub, Bart de Keizer, Jules Lavalaye, Jan Booij, Hebert Alberto Vargas, Michael J. Morris, André N Vis, Reindert van Moorselaar, Otto S. Hoekstra, Ronald Boellaard and Daniela E Oprea-Lager
Journal of Nuclear Medicine January 2019, jnumed.118.222505; DOI: https://doi.org/10.2967/jnumed.118.222505
Bernard H.E. Jansen
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerbrand M. Kramer
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthijs C.F. Cysouw
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maqsood M. Yaqub
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart de Keizer
2 UMC Utrecht, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jules Lavalaye
3 Sint Antonius Hospital, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Booij
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hebert Alberto Vargas
4 Memorial Sloan-Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Morris
4 Memorial Sloan-Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André N Vis
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reindert van Moorselaar
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto S. Hoekstra
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Boellaard
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela E Oprea-Lager
1 Amsterdam University Medical Centers, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Positron Emission Tomography (PET) is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers include 68Ga-Prostate-Specific Membrane Antigen HBED-CC (68Ga-PSMA), 18F-DCFPyL, 18F-fluoromethylcholine (18F-FCH) and 18F-dihydrotestosterone (18F-FDHT). Knowledge on the variability of tracer uptake in healthy tissues is important for accurate PET interpretation, since malignancy is suspected only if the uptake of a lesion contrasts with its background. Therefore, the aim of this study was to quantify uptake variability of PCa tracers in healthy tissues and identify stable reference regions for PET interpretation. Methods: A total of n = 232 PCa PET/CT scans from multiple hospitals was analyzed, including n = 87 68Ga-PSMA scans; n = 50 18F-DCFPyL scans; n = 68 18F-FCH scans and n = 27 18F-FDHT scans. Tracer uptake was assessed in the blood pool, lung, liver, bone marrow and muscle – using several Standarized Uptake Values (SUVmax, SUVmean, SUVpeak). Variability in uptake between patients was analyzed using the Coefficient of Variation (COV%). For all tracers, SUV reference ranges (95th percentiles) were calculated, which could be applicable as image-based Quality Control for future PET acquisitions. Results: For 68Ga-PSMA, the lowest uptake variability was observed in the blood pool (COV 19.9%), which was significantly more stable than all other tissues (COV 29.8-35.2%, P = 0.001-0.024). For 18F-DCFPyL, lowest variability was observed in the blood pool and liver (COV 14.4% and 21.7%, P = 0.001-0.003). The least variable 18F-FCH uptake was observed in the liver, blood pool and bone marrow (COV 16.8-24.2%, P = 0.001-0.012). For 18F-FDHT, low uptake variability was observed in all tissues, except the lung (COV 14.6-23.6%, P = 0.001-0.040). The different SUV-types had limited effect on variability (COVs within 3 percentage points). Conclusion: In this multicenter analysis, healthy tissues with limited uptake variability were identified, which may serve as reference regions for PCa PET interpretation. These reference regions include the blood pool for 68Ga-PSMA and 18F-DCFPyL, and the liver for 18F-FCH and 18F-FDHT. Healthy tissue SUV reference ranges are presented and applicable as image-based Quality Control.

  • Oncology: GU
  • PET/CT
  • Quality Assurance
  • PET interpretation
  • PSMA
  • healthy tissue
  • prostate cancer
  • Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (6)
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Healthy Tissue Uptake of 68Ga-Prostate Specific Membrane Antigen (PSMA), 18F-DCFPyL, 18F-Fluoromethylcholine (FCH) and 18F-Dihydrotestosterone (FDHT)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Healthy Tissue Uptake of 68Ga-Prostate Specific Membrane Antigen (PSMA), 18F-DCFPyL, 18F-Fluoromethylcholine (FCH) and 18F-Dihydrotestosterone (FDHT)
Bernard H.E. Jansen, Gerbrand M. Kramer, Matthijs C.F. Cysouw, Maqsood M. Yaqub, Bart de Keizer, Jules Lavalaye, Jan Booij, Hebert Alberto Vargas, Michael J. Morris, André N Vis, Reindert van Moorselaar, Otto S. Hoekstra, Ronald Boellaard, Daniela E Oprea-Lager
Journal of Nuclear Medicine Jan 2019, jnumed.118.222505; DOI: 10.2967/jnumed.118.222505

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Healthy Tissue Uptake of 68Ga-Prostate Specific Membrane Antigen (PSMA), 18F-DCFPyL, 18F-Fluoromethylcholine (FCH) and 18F-Dihydrotestosterone (FDHT)
Bernard H.E. Jansen, Gerbrand M. Kramer, Matthijs C.F. Cysouw, Maqsood M. Yaqub, Bart de Keizer, Jules Lavalaye, Jan Booij, Hebert Alberto Vargas, Michael J. Morris, André N Vis, Reindert van Moorselaar, Otto S. Hoekstra, Ronald Boellaard, Daniela E Oprea-Lager
Journal of Nuclear Medicine Jan 2019, jnumed.118.222505; DOI: 10.2967/jnumed.118.222505
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
  • Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Oncology: GU
  • PET/CT
  • Quality Assurance
  • PET interpretation
  • PSMA
  • healthy tissue
  • prostate cancer
SNMMI

© 2025 SNMMI

Powered by HighWire